Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Interpace Diagnostics Group Inc (NASDAQ:IDXG)

Delayed Data
As of Feb 11
 -0.035 / -11.67%
Today’s Change
Today|||52-Week Range
Health Services
Services to the Health Industry

Company Description

Interpace Diagnostics Group, Inc. provides outsourced commercial services to established and emerging pharmaceutical, biotechnology and healthcare companies in the U. S. It also provides other promotional services including clinical educator services, digital communications, teledetailing and with the formation of its new business unit, Interpace BioPharma which provides pharmaceutical, biotechnology, medical device and diagnostics clients with full-service product commercialization solutions. The company operates its business through the following segments: Commercial Services and Interpace Diagnostics. The Commercial Services segment focuses on providing outsourced pharmaceutical, biotechnology, medical device and diagnostic sales teams to corporate customers. The Interpace Diagnostics segment focuses on developing an commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.

Contact Information

Interpace Diagnostics Group, Inc.
Morris Corporate Center 1 Building A
Parsippany New Jersey 07054
P:(800) 242-7494
Investor Relations:



Individual stakeholders3.89%
Other institutional20.00%
Mutual fund holders17.44%

Top Executives

Jack E. StoverPresident, Chief Executive Officer & Director
Graham G. MiaoChief Financial Officer, Secretary & Treasurer
Rhonda De StefanoVice President & Associate General Counsel
Patrick K. KaneVice President & Controller
Steve RynkowskiVP-Learning, Development & Commercial Operations